Application of Gypensapogenin A to preparing drugs for treating yellow fever virus infection

A yellow fever virus and drug technology, applied in the field of biomedicine, to achieve huge social benefits and research value

Active Publication Date: 2013-01-16
南通三聚知识产权服务有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there have been no cases reported in China, but this does not make us relax our vigilance against the virus, because China's climate and geographical environment are complex, and there are many

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Gypensapogenin A to preparing drugs for treating yellow fever virus infection
  • Application of Gypensapogenin A to preparing drugs for treating yellow fever virus infection
  • Application of Gypensapogenin A to preparing drugs for treating yellow fever virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Embodiment 1: the preparation of the compound Gypensapogenin A tablet involved in the present invention:

[0037] Take 20 grams of compound Gypensapogenin A, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tabletting machine.

Embodiment 2

[0038] Embodiment 2: The preparation of the compound Gypensapogenin A capsules involved in the present invention:

[0039] Get 20 grams of compound Gypensapogenin A, add conventional auxiliary materials such as starch 180 grams for the preparation of capsules, mix well, and pack into capsules to make 1000 tablets.

[0040] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0042] A kind of application of Gypensapogenin A in the preparation treatment or prevention yellow fever virus infection medicine, its steps are:

[0043] A. Toxicity test of Gypensapogenin A on Vero cells

[0044] Vero cells (African green monkey kidney cells) are susceptible cells to YFV.

[0045] The experimental steps are as follows:

[0046] 1: Inoculate Vero cells: Use DMEM medium containing 10% (v / v) fetal bovine serum to make a single cell suspension, inoculate 1000-10000 cells per well into a 96-well cell culture plate, and inoculate a volume of 100ul per well ;

[0047] 2: Culture Vero cells: at 37°C, 5% (v / v) CO 2 Under culture conditions, cultivate for 2 days;

[0048] 3: Add Gypensapogenin A: Discard the DMEM medium in each well, add 100ul to each well and dilute to the corresponding concentration (0uM, 0.4uM, 1.2 uM, 3.7uM, 11uM, 33uM, 100uM, 300uM) Gypensapogenin A, add 100ul of DMEM medium without 10% (v / v) fetal bovine serum to the control well;

[0049]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of Gypensapogenin A to preparing drugs for treating or preventing yellow fever virus infection. Gypensapogenin A is capable of effectively inhibiting the proliferation of yellow fever virus, has little toxicity to cells, can be further developed as the drugs for treating diseases caused by virus infection and has extensive application prospect. The application of Gypensapogenin A to preparing the drugs for treating the yellow fever virus infection, disclosed by the invention, is firstly published, the framework type is brand new, the activity of inhibiting the yellow fever virus is unexpectedly strong and the probability of giving any revelation by other compounds does not exist, so that prominent substantive features are provided and a remarkable progress in preventing and treating the yellow fever virus infection is made at the same time.

Description

technical field [0001] The invention belongs to the field of biomedicine, and more specifically relates to the application of Gypensapogenin A in the preparation of medicines for treating or preventing yellow fever virus infection. Background technique [0002] Yellow fever virus (YFV) is a member of the Flavivirus genus in the family Flaviviridae. Yellow fever virus causes yellow fever, an acute infectious disease. Yellow fever has been designated as a quarantine infectious disease internationally, and China has also designated it as a Class A infectious disease. In 1648, an epidemic of yellow fever was first confirmed in the weekly YUCATAN peninsula. From the 17th to the 19th century, the disease was brought to Europe and North America through transportation. In almost two centuries, yellow fever became one of the most serious plagues in some parts of the United States, Africa, and Europe, causing a large number of deaths. Since the 20th century, the disease has not occ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/58A61P31/14
CPCY02A50/30
Inventor 施桦张广吴俊华
Owner 南通三聚知识产权服务有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products